ReviewFrontiers in pharmacology2021
Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 200 citations in OpenAlex.
- Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?Nutrients · 2025Trial
- Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework.Nutrients · 2026Review
- Natural Products as Nutritional Supplements in Human Disease Prevention and Management: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
- Resveratrol synergizes with chloroquine to inhibit the malignant progression of oral squamous cell carcinoma by regulating KIF11.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Potential Application of Cocoa Extract in Preventing Skin Cancer Through Inhibition of Adenosine Receptor A2, VEGFR-2, and BCL-2:Medeniyet medical journal · 2026Article
- Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine.International journal of molecular sciences · 2026Review
- Arctigenin Suppresses Breast Cancer Growth In Vitro and In Vivo Through Subtype-Specific Multi-Targeting Activity.International journal of molecular sciences · 2026Article
- An Overview of Metabolomic Approaches to Polyphenol Profiling for Nutraceutical Development.Molecules (Basel, Switzerland) · 2026Review
- In silico and in vitro insights into the wound-healing potential of syringic acid: protective and regenerative effects on human fibroblasts.BMC pharmacology & toxicology · 2026Article
- Ginkgetin: A Promising Multitarget Agent for Diverse Diseases.Biomolecules · 2026Review
- Article
- Novel Strategy for Cancer Therapy Proposal Based on Effects and Mechanisms of Targeting Cuproptosis by Polyphenols-A Narrative Review.Nutrients · 2026Review
- Mechanistic Insights into Active Components of Rosa Roxburghii Juice Against Fluoride-Induced Osteoarthritis.Antioxidants (Basel, Switzerland) · 2026Article
- Nanoencapsulation ofRSC advances · 2026Article
- Anti-cancer Mechanisms and Applications of Cinnamon Extract: A Comprehensive Review.Chinese journal of integrative medicine · 2026Review
- Recent Update Targeting Autophagy-Apoptosis Crosstalk Using Bioactive Natural Products for Ovarian Cancer Treatment.Biomedicines · 2026Review
- Natural Compounds in Gastric Cancer Therapy: Molecular Mechanisms and Potential Treatment Options.International journal of molecular sciences · 2026Review
- Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities.Oncology research · 2026Review
- Natural products as therapeutic interventions for inflammation-mediated cancer.Discover oncology · 2025Review
- Black Garlic: Evolution of the Chemical Composition and Broad Biological Activities.Journal of agricultural and food chemistry · 2025Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyphenols constitute an important group of natural products that are traditionally associated with a wide range of bioactivities. These are usually found in low concentrations in natural products and are now available in nutraceuticals or dietary supplements. A group of polyphenols that include apigenin, quercetin, curcumin, resveratrol, EGCG, and kaempferol have been shown to regulate signaling pathways that are central for cancer development, progression, and metastasis. Here, we describe novel mechanistic insights on the effect of this group of polyphenols on key elements of the signaling pathways impacting cancer. We describe the protein modifications induced by these polyphenols and their effect on the central elements of several signaling pathways including PI3K, Akt, mTOR, RAS, and MAPK and particularly those affecting the tumor suppressor p53 protein. Modifications of p53 induced by these polyphenols regulate p53 gene expression and protein levels and posttranslational modifications such as phosphorylation, acetylation, and ubiquitination that influence stability, subcellular location, activation of new transcriptional targets, and the role of p53 in response to DNA damage, apoptosis control, cell- cycle regulation, senescence, and cell fate. Thus, deep understanding of the effects that polyphenols have on these key players in cancer-driving signaling pathways will certainly lead to better designed targeted therapies, with less toxicity for cancer treatment. The scope of this review centers on the regulation of key elements of cancer signaling pathways by the most studied polyphenols and highlights the importance of a profound understanding of these regulations in order to improve cancer treatment and control with natural products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.